References
- Dickstein G, Schehner C, Nicholson WE et al. Adrenocorticotropin stimulation test: effects of basal cortisol level, time of day, and suggested new sensitive low dose test. J. Clin. Endocrinol. Metab.72, 773–778 (1991).
- Hamrahian AH, Tawakalitu SO, Arafah BM. Measurements of serum free cortisol in critically ill patients. N. Engl. J. Med.350, 1629–1638 (2004).
- Underwood LE, Attie KM, Baptista J. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J. Clin. Endocrinol. Metab.88, 5273–5280 (2003).
- Görges R, Knappe G, Gerl H et al. Diagnosis of Cushing’s syndrome: re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group. J. Endocrinol. Invest.22, 241–249 (1999).
- Yaneva M, Mosnier-Pudar H, Dugué M-A et al. Midnight salivary cortisol for the initial diagnosis of Cushing’s syndrome of various causes. J. Clin. Endocrinol. Metab.89, 3345–3351 (2004).
- Papanicolaou DA, Mullen N, Kyrou I et al. Nighttime salivary cortisol: a useful test for the diagnosis of Cushing’s syndrome. J. Clin. Endocrinol. Metab.87, 4515–4521 (2002).
- Weil RJ, Vortmeyer AO, Nieman LK et al. Surgical remission of pituitary adenomas confined to the neurohypophysis in Cushing’s disease. J. Clin. Endocrinol. Metab.91, 2656–2664 (2006).
- Chen JC, Amar AP, Choi S et al. Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. J. Neurosurg.98, 967–973 (2003).
- Atkinson AB, McCance DR, Kennedy L et al. Cyclical Cushing’s syndrome first diagnosed after pituitary surgery: a trap for the unwary. Clin. Endocrinol.36, 297–300 (1992).
- Freda PU, Post KD, Powell JS et al. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J. Clin. Endocrinol. Metab.83, 3808–3816 (1998).
- Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab.89, 667–674 (2004).
- Lansang C, Chitaia N, Simpson N et al. Serum IGF-1 levels in treated acromegaly: how normal is “normal”? Pituitary8, 135–138 (2005).
- Lamberts SWJ, van der Lely A-J, de Herder WW et al. Octreotide. N. Engl. J. Med.334, 246–254 (1996).
- Robertson GL. The use of vasopressin assays in physiology and pathophysiology. Semin. Nephrol.4, 368–383 (1994).
- Loh JA, Verbalis JG. Disorders of water and salt metabolism associated with pituitary disease. Endocrinol. Metab. Clin. North Am.37, 213–234 (2008).
- Loh JA, Verbalis JG. Diabetes insipidus as a complication after pituitary surgery. Nat. Clin. Pract. Endocrinol. Metab.3, 489–494 (2007).
- Schlechte JA. Prolactinoma. N. Engl. J. Med.349, 2035–2041 (2003).
- Molitch ME. Medical treatment of prolactinomas. Endocrinol. Metab. Clin. North Am.28, 143–169 (1999).
- Jeffcoat WJ, Pound N, Sturrock ND et al. Long-term follow-up of patients with hyperprolactinaemia. Clin. Endocrinol.45, 299–303 (1996).
- Colao A, Galderisi M, Di Sarno A et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J. Clin. Endocrinol. Metab.93, 3777–3784 (2008).
- Colao A, Di Sarno A, Cappabianco P et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl. J. Med.349, 2023–2033 (2003).
- Brada M, Burchell L, Ashley S et al. The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int. J. Radiat. Oncol. Biol. Phys.45, 693–698 (1999).
- Becker G, Kocher M, Kortmann RD et al. Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther. Onkol.178, 173–186 (2002).